The Original Investigation titled “Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation,”1 published in the December 21, 2021, issue of JAMA, included an error in the 95% CIs for the hazard ratios for hemorrhagic events and nonfatal extracranial bleeding in Figure 3. The figure has been corrected and now includes the accurate 95% CIs for the hazard ratio for hemorrhagic events (1.11-1.47) and nonfatal extracranial bleeding (2.26-2.63). (All other information in the figure was correct and is unchanged.)
References
- 1.Ray WA, Chung CP, Stein CM, et al. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA. 2021;326(23):2395-2404. doi: 10.1001/jama.2021.21222 [DOI] [PMC free article] [PubMed] [Google Scholar]